329-89-5
基本信息
2-氨基吡啶-5-甲酰胺
6-氨基-3-吡啶甲酰胺
6-氨基尼克酰胺
6-氨基维生素PP
6-AMINO-3-PYRIDINECARBOXAMIDE
6-AMINONICOTINAMIDE
6-AMINOPYRIDINE-3-CARBOXAMIDE
2-Amino-5-carbamoylpyridine
3-Pyridinecarboxamide, 6-amino-
6-amino-3-pyridinecarboxamid
6-amino-nicotinamid
6-Aminonicotinic acid amide
6-aminonicotinicacidamide
6-Amino-nicotinsaeureamid
6-Aminonikotinsaeureamid
6-AN
6-ANA
Aminonicotinamide
FDA 0121
fda0121
NSC 21206
nsc21206
U-8774
物理化学性质
外观性质 | 白色结晶性粉末。100ml水可溶0.3g,不溶于一般有机溶剂。有致畸可能性。熔点:245-248℃ |
熔点 | 245-248 °C(lit.) |
沸点 | 251.97°C (rough estimate) |
密度 | 1.2620 (rough estimate) |
折射率 | 1.6910 (estimate) |
储存条件 | Keep in dark place,Inert atmosphere,Room temperature |
溶解度 | insoluble in H2O; insoluble in EtOH; ≥13.7 mg/mL in DMSO |
酸度系数(pKa) | 15.66±0.50(Predicted) |
形态 | 粉末晶体 |
颜色 | 白色至浅黄色 |
水溶解性 | Soluble in Dimethyl sulfoxide (DMSO). Insoluble in water. |
BRN | 116042 |
CAS 数据库 | 329-89-5(CAS DataBase Reference) |
NIST化学物质信息 | Nicotinamide, 6-amino-(329-89-5) |
EPA化学物质信息 | 6-Aminonicotinamide (329-89-5) |
安全数据
危险性符号(GHS) | GHS08 |
警示词 | 危险 |
危险性描述 | H360FD |
防范说明 | P201-P308+P313 |
危险品标志 | T |
危险类别码 | R61 |
安全说明 | S53-S45 |
危险品运输编号 | 1655 |
WGK Germany | 3 |
RTECS号 | US4550000 |
Hazard Note | Toxic |
危险等级 | 6.1 |
包装类别 | II |
海关编码 | 29333990 |
329-89-5(安全特性,毒性,储运)
图谱信息
6-氨基烟酰胺(329-89-5)质谱(MS)6-氨基烟酰胺(329-89-5)核磁图(1HNMR)6-氨基烟酰胺(329-89-5)核磁图(13CNMR)6-氨基烟酰胺(329-89-5)红外图谱(IR1)6-氨基烟酰胺(329-89-5)红外图谱(IR2)6-氨基烟酰胺(329-89-5)Raman光谱知名试剂公司产品信息
6-Aminonicotinamide,>99.0%(T)(329-89-5) TCI Shanghai
6-氨基烟酰胺价格(试剂级)
报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
2024/11/08 | L06692 | 6-氨基烟酰胺, 99% 6-Aminonicotinamide, 99% | 329-89-5 | 1g | 739元 |
2024/11/08 | L06692 | 6-氨基烟酰胺, 99% 6-Aminonicotinamide, 99% | 329-89-5 | 5g | 2914元 |
2024/11/08 | 10415 | 6-氨基烟酰胺 6-Aminonicotinamide, 98%, Thermo Scientific Chemicals | 329-89-5 | 1g | 1330元 |
常见问题列表
Target | Value |
G6PD
(Cell-free assay) | 0.46 μM(Ki) |
6-Aminonicotinamide (100 nM; 7 days) causes a significant decrease in the human AR+, hormone-sensitive prostate cancer cell lines LNCaP and LAPC4, as well as the CRPC-derivative C4-2 and 22Rv1 cell models. 6-Aminonicotinamide (100 nM ± 10 nM R1881 as indicated for 3 days) increases both basal- and R1881-mediated ROS levels, suggesting 6-Aminonicotinamide is blocking the cells' antioxidant defense. 6-Aminonicotinamide also increases ROS levels in C4-2 cells.
6-Aminonicotinamide (20 mg/kg; i.p.; thress times; days 1, 10 or 11, and 21) alone induces a small but significant tumor growth delay (4.3+/-0.8 days). Treatment with 6-Aminonicotinamide followed by radiation induces a tumor growth delay of 57.0+/-3.8 days in CD8F1 breast tumor model.